JP2024527565A - Ｍａｐ４ｋ１阻害物質として使用するためのピリミジン化合物 - Google Patents

Ｍａｐ４ｋ１阻害物質として使用するためのピリミジン化合物 Download PDF

Info

Publication number
JP2024527565A
JP2024527565A JP2024500151A JP2024500151A JP2024527565A JP 2024527565 A JP2024527565 A JP 2024527565A JP 2024500151 A JP2024500151 A JP 2024500151A JP 2024500151 A JP2024500151 A JP 2024500151A JP 2024527565 A JP2024527565 A JP 2024527565A
Authority
JP
Japan
Prior art keywords
amino
chloro
methoxy
pyrimidin
tetrahydroisoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527565A5 (https=
Inventor
アイヤー，プラヴィン
ダス，サンジブ
チンナパッツ，ムルガン
チョードリー，サチン
サイニ，ジャグモハン
マンダディ，スラヴァン
ゴウダ，ナガラジ
ダーレ，ディーニャネシュワル
パティル，サンディップ
カドラグ，ナナサヘブ
ミスラ，チャンドラセカール
パンゲラ，プリヤンカー
Original Assignee
グレンマーク・スペシャルティー・エスエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グレンマーク・スペシャルティー・エスエー filed Critical グレンマーク・スペシャルティー・エスエー
Publication of JP2024527565A publication Critical patent/JP2024527565A/ja
Publication of JP2024527565A5 publication Critical patent/JP2024527565A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024500151A 2021-07-06 2022-07-06 Ｍａｐ４ｋ１阻害物質として使用するためのピリミジン化合物 Pending JP2024527565A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121030204 2021-07-06
IN202121030204 2021-07-06
PCT/IB2022/056248 WO2023281417A1 (en) 2021-07-06 2022-07-06 Pyrimidine compounds for use as map4k1 inhibitors

Publications (2)

Publication Number Publication Date
JP2024527565A true JP2024527565A (ja) 2024-07-25
JP2024527565A5 JP2024527565A5 (https=) 2024-09-11

Family

ID=82703212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500151A Pending JP2024527565A (ja) 2021-07-06 2022-07-06 Ｍａｐ４ｋ１阻害物質として使用するためのピリミジン化合物

Country Status (14)

Country Link
US (1) US12577267B2 (https=)
EP (1) EP4367123A1 (https=)
JP (1) JP2024527565A (https=)
KR (1) KR20240012538A (https=)
CN (1) CN117730083A (https=)
AU (1) AU2022305807B2 (https=)
CA (1) CA3223874A1 (https=)
CL (1) CL2023003791A1 (https=)
CO (1) CO2024000572A2 (https=)
EC (1) ECSP24007193A (https=)
IL (1) IL309342A (https=)
MX (1) MX2023015246A (https=)
PE (1) PE20240585A1 (https=)
WO (1) WO2023281417A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231875A1 (en) 2023-05-09 2024-11-14 Glenmark Specialty S.A. Hpk1 inhibitor for use in the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015025197A1 (en) * 2013-08-22 2015-02-26 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
JP2020503271A (ja) * 2016-11-30 2020-01-30 アリアド ファーマシューティカルズ， インコーポレイテッド 造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ
WO2021125803A1 (ko) * 2019-12-16 2021-06-24 한국화학연구원 신규한 피리미딘 유도체 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015025197A1 (en) * 2013-08-22 2015-02-26 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
JP2020503271A (ja) * 2016-11-30 2020-01-30 アリアド ファーマシューティカルズ， インコーポレイテッド 造血前駆体キナーゼ１（ｈｐｋ１）阻害剤としてのアニリノピリミジンａｓ
WO2021125803A1 (ko) * 2019-12-16 2021-06-24 한국화학연구원 신규한 피리미딘 유도체 및 이의 용도

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LACEY, BRIAN M. 他: "Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors", SLAS DISCOVERY, vol. 26(1), JPN6025033382, 2021, pages 88 - 99, ISSN: 0005666738 *
STAMBIRSKYI, MAKSYM V. 他: "Phosphine Oxides (-POMe2) for Medicinal Chemistry: Synthesis, Properties, and Applications", JOURNAL OF ORGANIC CHEMISTRY, vol. 86(18), JPN6025033384, 2021, pages 12783 - 12801, ISSN: 0005666740 *
VARA, BRANDON A. 他: "Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compoun", ACS MEDICINAL CHEMISTRY LETTERS, vol. 12(4), JPN6025033383, 2021, pages 653 - 661, ISSN: 0005666739 *

Also Published As

Publication number Publication date
AU2022305807A1 (en) 2024-01-04
AU2022305807B2 (en) 2024-09-05
US20230227483A1 (en) 2023-07-20
MX2023015246A (es) 2024-01-19
CN117730083A (zh) 2024-03-19
US12577267B2 (en) 2026-03-17
WO2023281417A1 (en) 2023-01-12
CA3223874A1 (en) 2023-01-12
PE20240585A1 (es) 2024-03-21
CL2023003791A1 (es) 2024-07-12
CO2024000572A2 (es) 2024-02-05
IL309342A (en) 2024-02-01
KR20240012538A (ko) 2024-01-29
ECSP24007193A (es) 2024-03-01
EP4367123A1 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
US10807982B2 (en) Bromodomain inhibitors
JP7451765B2 (ja) Ｃｄｋ阻害剤としてのピリジンアセトアミド系誘導体、その調製方法及び用途
US11242334B2 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JP6461097B2 (ja) Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物
US9862707B2 (en) TrkA kinase inhibitors, compositions and methods thereof
TWI520962B (zh) As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
TW202039489A (zh) Mat2a之雜雙環抑制劑及用於治療癌症之使用方法
CN115703775A (zh) 一种kras突变体g12c抑制剂及其制备方法和应用
JP7101311B2 (ja) Ｍａｐ４ｋ１阻害剤として使用するためのインドリノン化合物
CN112601752A (zh) Map4k1的新颖抑制剂
CN113508116B (zh) 吡唑并[1,5-a]吡啶类衍生物、及其制备方法和用途
AU2005289644A1 (en) Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
HK1217482A1 (en) Enzyme modulators and therapies
TW201506028A (zh) １，２-雙取代雜環化合物
HK1210608A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
WO2013170774A1 (zh) 具有抗肿瘤活性的乙炔衍生物
TWI553011B (zh) 雜芳族化合物以及其作為多巴胺ｄ１配體的用途
JP2009528374A (ja) ホスホジエステラーゼ１０阻害剤
JP2025517106A (ja) Ｐａｒｐ１阻害剤としての化合物
CN119451964A (zh) Fgfr2和fgfr3抑制剂及其用途
JP2024527565A (ja) Ｍａｐ４ｋ１阻害物質として使用するためのピリミジン化合物
JP2025525395A (ja) Ｄｙｒｋ／ｃｌｋの低分子阻害剤およびその使用
EA048523B1 (ru) Пиримидиновые соединения для применения в качестве ингибиторов map4k1
OA21470A (en) Pyrimidine compounds for use as MAP4K1 inhibitors.
CN118420607A (zh) 杂芳环化合物及其应用

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260217